Osaka Rie, Muraoka Yuki, Miwa Yuko, Manabe Koichiro, Kobayashi Mamoru, Takasago Yukari, Ooto Sotaro, Murakami Tomoaki, Suzuma Kiyoshi, Iida Yuto, Tsujikawa Akitaka
Department of Ophthalmology, Kagawa University Faculty of Medicine, Miki, Japan.
Ophthalmologica. 2018;239(1):27-35. doi: 10.1159/000479049. Epub 2017 Sep 26.
To compare the 12-month efficacy of 1 initial intravitreal injection of an anti-vascular endothelial growth factor (VEGF) agent followed by pro re nata (PRN) dosing with that of 3 initial monthly injections followed by PRN dosing in patients with macular edema (ME) after central retinal vein occlusion (CRVO).
Twenty-nine eyes received 1 initial injection (1+PRN group) and 20 received 3 monthly injections (3+PRN group).
At month 12, changes in logMAR visual acuity from baseline were -0.172 ± 0.372 and -0.142 ± 0.317 in the 1+PRN and 3+PRN groups, respectively; the difference was not significant (p = 0.769). The number of anti-VEGF injections administered in the 3+PRN group (5.9 ± 2.1) was significantly greater than that in the 1+PRN group (4.1 ± 2.8; p = 0.022).
When used for ME after CRVO, a 1+PRN regimen achieved 12-month outcomes similar to those of a 3+PRN regimen with fewer injections.
比较玻璃体内单次注射抗血管内皮生长因子（VEGF）药物后按需给药与每月初始注射3次后按需给药对视网膜中央静脉阻塞（CRVO）后黄斑水肿（ME）患者的12个月疗效。
29只眼接受单次初始注射（1+PRN组），20只眼接受每月3次初始注射（3+PRN组）。
在第12个月时，1+PRN组和3+PRN组的logMAR视力较基线的变化分别为-0.172±0.372和-0.142±0.317；差异无统计学意义（p = 0.769）。3+PRN组抗VEGF注射次数（5.9±2.1）显著多于1+PRN组（4.1±2.8；p = 0.022）。
用于CRVO后ME时，1+PRN方案与3+PRN方案12个月疗效相似，但注射次数更少。
Zotero 插件